Denosumab May Shield Joints in Osteoporosis Patients
Using Japanese claims data (2015–2024), new denosumab users had a 16% lower 3-year risk of developing osteoarthritis vs new oral bisphosphonate users (relative risk 0.84; 95% CI 0.73–0.89), especially for knee and hip OA. The benefit was not significant for those who switched from bisphosphonates to denosumab. Given the observational design and potential confounding, findings should be interpreted with caution and require clinically validated OA outcomes.
